Overview

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM) patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

European Myeloma Network
Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators:

Fondazione EMN Italy Onlus
Fondazione Neoplasie Sangue Onlus

Treatments:

BB 1101
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate